天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Pediatrics International >>article
Pediatrics International

Pediatrics International

IF: 1
Download PDF

Ferrous sulfate oral solution in young children with iron deficiency anemia: An open-label trial of efficacy, safety, and acceptability.

Published:1 July 2020 DOI: 10.1111/ped.14237 PMID: 32191814
Lidia Pachuta W?gier, Maciej Kubiak, Agata Liebert, Thierry Clavel, Agnès Montagne, Aline Stennevin, Sandrine Roye, Asmaa Boudribila

Abstract

Background: This study evaluated the efficacy, safety, and acceptability of a new ferrous sulfate oral solution (Tardyferon? 20?mg/mL) in young children with mild or moderate iron deficiency anemia (IDA).

Methods: This was a multicenter, national, single-arm, open-label study. Children aged 6-53?months presenting with mild or moderate IDA (i.e.,?blood hemoglobin (Hb) ranging from?7.0?to?10.9?g/dL and serum ferritin <12?ng/mL) were eligible for inclusion. The ferrous sulfate heptahydrate solution (2?mg/kg/day) was administered orally for 3?months. If normalization of either Hb or ferritin was not achieved at month?3 the treatment was continued for another 3?months.

Results: Of the 100 children screened, 21 aged 6-17?months were included and received the study treatment, and 19 were analyzed for hematologic outcomes at month?3. Only one patient continued treatment for the additional 3?months. At month?3, mean ± SD Hb and ferritin levels were 12.0 ± 0.7?g/dL and 31.5 ± 19.4?ng/mL, respectively. Hemoglobin and ferritin levels were normalized in 95% (18/19) and 84% (16/19) of the patients, respectively. Treatment compliance and levels of satisfaction of both the parents and the investigators were high. Overall, 33.3% of patients (7/21) experienced at least one adverse event. Only one patient (4.8%) experienced a drug-related adverse event (upper abdominal pain).

Conclusions: A 2?mg/kg daily dose of the new oral ferrous sulfate heptahydrate solution provides substantial therapeutic benefit with high levels of tolerability in young children who have mild or moderate IDA.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
FERROUS SULFATE 7720-78-7 FeO4S 524 suppliers Inquiry
Ferrous sulfate heptahydrate 7782-63-0 FeH14O11S 507 suppliers $5.00-$5640.00
tardyferon 75285-30-2 - Inquiry

Similar articles

IF:16.4

Efficacy and Safety of Microsomal Ferric Pyrophosphate Supplement for Iron Deficiency Anemia in Pregnancy

Neural Regeneration Research Ankita Srivastav, Shilpa Kshirsagar,etc Published: 28 March 2024
IF:5.9

Use of ferrous fumarate to fortify foods for infants and young children.

Neural Regeneration Research Richard Hurrell,etc Published: 1 September 2010
IF:0

Efficacy and safety of crisaborole ointment in pediatric atopic dermatitis: A 4-week open-label study

Neural Regeneration Research Abhishek De, Disha Chakraborty,etc Published: 12 February 2024